A Cold Case: Cold Agglutinin Disease Complicating Stem Cell Transplant.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: life-threatening hematologic diseases
I · Intervention 중재 / 시술
a 9/10 HLA-mismatched unrelated peripheral blood stem cell transplant
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
A subsequent CD34-selected stem cell boost from the same donor on Day +108 posttransplant, confirmed to be CAS-negative, resulted in successful platelet engraftment and recovery. This case highlights the potential complications of CAS in donors, emphasizing the need for comprehensive donor evaluation and management strategies to mitigate adverse effects on recipients.
Allogeneic hematopoietic cell transplants (HCTs) offer a curative option for patients with life-threatening hematologic diseases.
APA
Al-Nazer MW, Alsammerai S, et al. (2026). A Cold Case: Cold Agglutinin Disease Complicating Stem Cell Transplant.. Case reports in transplantation, 2026, 6270387. https://doi.org/10.1155/crit/6270387
MLA
Al-Nazer MW, et al.. "A Cold Case: Cold Agglutinin Disease Complicating Stem Cell Transplant.." Case reports in transplantation, vol. 2026, 2026, pp. 6270387.
PMID
41743542
Abstract
Allogeneic hematopoietic cell transplants (HCTs) offer a curative option for patients with life-threatening hematologic diseases. While stem cell infusion reactions are common, they are generally not severe and typically do not affect engraftment. We present a rare case of isolated secondary cold agglutinin syndrome (CAS) in a donor, complicating the graft infusion and causing poor graft function (PGF) in a recipient. The 27-year-old recipient, diagnosed with refractory T-cell acute lymphoblastic leukemia (ALL), underwent a 9/10 HLA-mismatched unrelated peripheral blood stem cell transplant. The donor developed an upper respiratory infection 1 week before the donation, and cold agglutinin antibodies were detected in the donor's stem cell product. During infusion, the patient developed fever, tachycardia, and hypertension. Despite initial neutrophil engraftment and full donor chimerism, the patient remained transfusion-dependent, indicating PGF. A subsequent CD34-selected stem cell boost from the same donor on Day +108 posttransplant, confirmed to be CAS-negative, resulted in successful platelet engraftment and recovery. This case highlights the potential complications of CAS in donors, emphasizing the need for comprehensive donor evaluation and management strategies to mitigate adverse effects on recipients.